Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Ovarian Cancer
DRUG: Pamiparib capsule|DRUG: Placebo capsule
Progression free survival (PFS) by blinded Independent Review Committee (BIRC) assessment, up to 8 years
Overall survival, up to 9 years|Objective response rate by investigator assessment, up to 2 years|Duration of response by investigator assessment, up to 2 years|PFS by investigator assessment, up to 8 years|Time to response by investigator assessment, up to 8 years|Number of participants with treatment-emergent adverse events (TEAEs), up to 9 years
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy